ECT2 BRCT domains (human, recombinant)

Epithelial Cell-transforming Sequence 2 Oncogene

Epithelial cell-transforming sequence 2 oncogene (ECT2) is a guanine nucleotide exchange factor (GEF) that catalyzes the exchange of GDP for GTP from small GTPases of the Rho family, such as RhoA, RhoC, Rac1, and Cdc42.{24795} ECT2 GEF activity plays an essential role during cytokinesis.{24792} ECT2 contains a DH (DBL-homology) domain, a pleckstrin homology (PH) domain and tandem BRCT domains.{24794} BRCT domains are modular units of ~100 amino acids that fold independently and recognize linear phosphoserine or phosphothreonine regions to mediate protein-protein and protein-DNA interactions.{23632,22097} BRCT domains were initially recognized in the C-terminal region of the breast cancer protein BRCA1, as well as the p53 binding protein and the yeast cell cycle checkpoint protein RAD9.{23633} BRCT domains often occur as tandem repeats at the C-terminal end of several proteins that are functionally diverse.{22097} Most BRCT domain-containing proteins participate in DNA-damage checkpoint control or DNA-repair pathways, or both.{23634,23633} The BRCT domains of ECT2 make intramolecular interactions with the C-terminal DH/PH domains of the protein, thus, masking the catalytic GEF activity for Rho GTPases.{24796} Additionally, release of the autoinhibition by the BRCT domains may be necessary for the proper functioning of ECT2 during cytokinesis.{24796} Expression levels of ECT have been shown to be strongly correlated with prognosis in glioma patients.{24793}

-80

-80

50 mM Tris, pH 7.5, with 500 mM sodium chloride, 5% glycerol, and 5 mM β-mercaptoethanol

365

≥90%